Glaxo Wellcome PLC
Division of GlaxoSmithKline PLC
Latest From Glaxo Wellcome PLC
Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.
Takeda is aiming to get ahead in what it believes is an emerging area with big potential in immunotherapy: gamma delta T-cells. It has signed a deal with GammaDelta Therapeutics that gives it a purchase option on the UK-based, Abingworth-backed start-up. GammaDelta's CEO, former GSK executive Paolo Paoletti, and the head of Takeda's external innovation center, Dan Curran, spoke to Scrip.
Since being promoted to chief scientific officer of Bristol-Myers Squibb, effective July 2013, company veteran Francis Cuss says he has aimed for continuity while staying flexible to respond to breaking science. In an interview at the J.P. Morgan Healthcare Conference in January, he explains the company’s thinking when it comes to focusing on particular disease areas with the highest unmet need and potential for speedy development.
Established in January 2012 on the foundation of Takeda’s long-standing domestic pediatric vaccine business, the new initiative will be global in scale, building on the territorial gains from the Nycomed acquisition, and led by a seasoned player.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Robert A Ingram, CEO
J. D Coombe, Executive Dir., Fin & Investor Relations
James Neidel, Executive Dir., R&D
Richard Sykes, Chmn.
- Contact Info
Glaxo Wellcome PLC
Phone: (44) 1714 9340
London, W1X 6BQ
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.